Altria Group Inc. (MO)
MO trades on NYSE in Health Care, Medicinal Chemicals and Botanical Products . Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/764180/000076418026000017/0000764180-26-000017-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | MO on NYSE |
| Sector | Health Care |
| Industry | Medicinal Chemicals and Botanical Products |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000764180 |
| SEC industry code | Cigarettes |
| Incorporated in | VA |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $23.3B |
| Net income | $6.9B |
| Operating income | $9.9B |
| Net margin | 29.8% |
| Operating margin | 42.5% |
| Revenue growth | -3.1% |
| Cash | $4.5B |
| Total assets | $35.0B |
| P/E (computed) | 18.9× |
| P/S (computed) | 5.6× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-10-29 |
| Cash and burn | $2.7B cash; operating cash flow $2.4B a quarter. | Report 2026-09-30 |
| Shares outstanding | 1,663,436,915 (2026-10-21); 1,678,671,552 a year earlier; 1,768,646,674 three years earlier. | Cover page 2026-10-21 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-10-29 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Delisting | 25-NSE filed | 25-NSE 2025-06-16 |
| Auditor | PricewaterhouseCoopers LLP, Richmond, Virginia, United States | PCAOB Form AP 2026-02-10 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $101K, sold $2.4M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $6.1B | $2.5B | $3.1B | $2.7B | $24.1B | $23.5B | 10-Q 2026-10-29 |
| Q2 2026 2026-06-30 | $6.1B | $2.3B | $719.0M | $2.4B | $24.6B | $23.5B | 10-Q 2026-07-30 |
| Q1 2026 2026-03-31 | $5.4B | $2.2B | $2.3B | $3.5B | $24.6B | $23.4B | 10-Q 2026-04-30 |
| Q4 2025 2025-12-31 | $5.8B | $1.1B | $3.3B | $4.5B | $25.7B | $23.3B | 10-K 2026-02-25 |
| Q3 2025 2025-09-30 | $6.1B | $2.4B | $3.1B | $3.5B | $25.7B | $23.4B | 10-Q 2026-10-29 |
| Q2 2025 2025-06-30 | $6.1B | $2.4B | $205.0M | $1.3B | $24.7B | $23.6B | 10-Q 2026-07-30 |
| Q1 2025 2025-03-31 | $5.3B | $1.1B | $2.7B | $4.7B | $26.1B | $23.7B | 10-Q 2026-04-30 |
| Q4 2024 2024-12-31 | $6.0B | $3.0B | $3.3B | $3.1B | $24.9B | $24.0B | 10-K 2026-02-25 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2026-10-29 |
| Latest annual report | 10-K/A | 2026-05-27 |
| Latest quarterly / interim | 10-Q | 2026-10-29 |
| Latest current report | 8-K | 2026-10-29 |
| Latest proxy | DEFA14A | 2026-04-02 |
Source: SEC EDGAR submissions feed, 1,006 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +3.3% |
| 1 month | +9.9% |
| 3 months | +20.8% |
| Year to date | +36.4% |
| 1 year | +36.0% |
| From 52-week high | 0.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Medicinal Chemicals and Botanical Products
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| BTI | British American Tobacco Industries p.l.c. Common Stock ADR | $62.11 | +0.36% | $134.2B |
| PM | Philip Morris International Inc | $196.04 | -1.47% | $305.6B |
| DFTX | Definium Therapeutics Inc. Common Shares | $30.16 | -5.99% | $4.1B |
| RGC | Regencell Bioscience Holdings Limited | $4.72 | -4.45% | $2.3B |
| TRLV | Trulieve Cannabis Corp. Subordinate Voting Shares | $10.33 | -5.23% | $2.0B |
| RLX | RLX Technology Inc. | $1.53 | -1.92% | $1.9B |
| CRON | Cronos Group Inc. Common Share | $3.27 | -3.25% | $1.2B |
| OBIO | Orchestra BioMed Holdings Inc. | $7.12 | -1.79% | $560.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier